Orthofix Medical Inc. - 8-K Filing
Orthofix expects Medicare reimbursement for non-invasive bone growth stimulators to decline by ~10% due to FDA reclassification and CMS billing changes effective May 2026, leading the company to revise its full-year 2026 guidance: net sales of $838–$848 million and adjusted EBITDA of $90–$93 million. The firm no longer expects positive free cash flow for 2026 and has suspended its three-year financial targets. (Items: 7.01 Regulation FD Disclosure)
Tickers: $OFIX